Trusted Resource for Clinical Trials, Protocols & Progress
Special contexts where PRIME has unique implications:
Rare Diseases: PRIME supports flexible trial designs with small cohorts.
Oncology: PRIME accelerates high-priority oncology trials with adaptive endpoints.
Advanced Therapies (ATMPs): PRIME works closely with EMA’s CAT to address complex development pathways.
Pediatrics: PRIME overlaps with mandatory PIPs, requiring early alignment.
Bridging studies in India serve a critical function in ensuring that foreign clinical data is relevant, safe, and effective for Indian patients. Sponsors should adopt a proactive strategy, understand CDSCO expectations, align their global and Indian regulatory plans, and where possible, integrate Indian cohorts into global trials. Bridging studies, though sometimes seen as additional burdens, can significantly strengthen local market access and post-approval confidence.
Click to read the full article.
Sponsors should: (1) validate devices rigorously; (2) engage FDA early regarding wearable endpoints; (3) ensure interoperability and cybersecurity; (4) establish SOPs for device use; (5) train patients effectively; (6) monitor adherence remotely; (7) implement quality assurance programs for wearable data; (8) conduct pilot studies before pivotal trials; (9) engage with patient advocacy groups; and (10) prepare inspection-ready documentation of wearable integration.
Click to read the full article.
Phase 3 global trials in the UK highlight both the strengths and challenges of conducting large-scale research within the NHS framework. While MHRA oversight ensures robust compliance, recurring issues such as TMF quality, SAE reporting delays, and recruitment bottlenecks demand ongoing sponsor attention. Case studies from oncology, cardiovascular, rare disease, and vaccine trials demonstrate the importance of early planning, NIHR integration, and proactive regulatory engagement. By applying lessons learned from past experiences, sponsors and CROs can strengthen the UK’s position as a reliable hub for global Phase 3 development.
Click to read the full article.
Investigator training varies across trial types:
Pediatrics: Requires additional focus on assent processes and child-specific ethics.
Oncology: Emphasizes SAE management, complex endpoints, and protocol adherence.
ATMPs: Training must address long-term follow-up and specialized handling of gene/cell therapies.
Decentralized Trials: Investigators must be trained on digital platforms and remote monitoring procedures.
Sponsors should: (1) implement Part 11-compliant systems; (2) test comprehension with participants; (3) train investigators and coordinators in eConsent use; (4) provide multilingual content; (5) ensure HIPAA compliance; (6) establish audit trails; (7) integrate eConsent into clinical trial workflows; (8) validate technology prior to deployment; (9) monitor ongoing compliance; and (10) involve IRBs early in design and implementation.
Click to read the full article.
PvPI is a cornerstone of India’s pharmacovigilance ecosystem. It plays a pivotal role in ensuring clinical trial safety through SAE data aggregation, global collaboration, and risk signal detection. Sponsors and clinical trial teams must proactively engage PvPI to meet regulatory expectations and safeguard participant welfare throughout the drug development lifecycle.
Click to read the full article.
Sponsors should: (1) establish dedicated teams for post-approval commitments; (2) maintain proactive communication with FDA; (3) integrate RWE sources with traditional trial data; (4) conduct feasibility assessments for long-term follow-up; (5) align global post-marketing requirements with FDA obligations; (6) track commitments with compliance dashboards; (7) engage CROs with long-term study expertise; (8) involve patient advocacy groups; (9) maintain inspection readiness; and (10) implement CAPA systems for delays or deficiencies.
Click to read the full article.
The Trial Master File is the backbone of clinical trial compliance in the UK. MHRA inspections consistently highlight TMF deficiencies, making it essential for sponsors, CROs, and NHS Trusts to prioritise robust documentation practices. From validation of eTMFs to archiving strategies, compliance with UK TMF requirements ensures trial integrity, supports global submissions, and protects patient safety. A proactive approach to TMF governance remains the best strategy for inspection readiness and long-term compliance.
Click to read the full article.
Benchmarking must account for trial-specific and population-specific factors:
Rare Diseases: Low patient availability makes recruitment benchmarks less comparable across Member States.
Oncology Trials: High SAE rates influence pharmacovigilance benchmarks, requiring more resources.
Pediatrics: Regulatory requirements for assent and guardian consent may extend timelines.
Advanced Therapies (ATMPs): Logistics of cell/gene therapy administration complicate benchmarking metrics across states.
